Clinical Challenges: Treating AML in Older and Unfit Patients
MedPage Today,
Clinical Challenges > ASH: AML Lower-intensity therapies now available and effective for these patients by Mike Bassett, Staff…
Clinical Challenges > ASH: AML Lower-intensity therapies now available and effective for these patients by Mike Bassett, Staff…
The phase 3 ASCERTAIN - AML clinical study of decitabine and cedazuridine, administered orally as a fixed-dose combination (ASTX7…
The phase 3 ASCERTAIN - AML clinical study of decitabine and cedazuridine, administered orally as a fixed-dose combination (ASTX7…
The phase 3 ASCERTAIN - AML clinical study of decitabine and cedazuridine, administered orally as a fixed-dose combination (ASTX7…
The phase 3 ASCERTAIN - AML clinical study of decitabine and cedazuridine, administered orally as a fixed-dose combination (ASTX7…
The phase 3 ASCERTAIN - AML clinical study of decitabine and cedazuridine, administered orally as a fixed-dose combination (ASTX7…
A diagnosis of acute myeloid leukemia (AML) is particularly challenging in older adults, whose age makes them highly…
The U.S. Food and Drug Administration (FDA) has approved Pfizer Inc.'sDaurismo(glasdegib), a once-daily oral medicine, for the…
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today announced that the U.S.
NEW YORK--(BUSINESS WIRE)--Pfizer, Inc. (NYSE:PFE) today announced that the U.S.
DAURISMO is the first and only Hedgehog pathway inhibitor approved for the treatment of AML In a randomized Phase 2 trial…
DAURISMO is the first and only Hedgehog pathway inhibitor approved for the treatment of AML In a randomized Phase 2 trial…
NEW YORK--(Business Wire)--Pfizer Inc. (NYSE:PFE) today announced that the U.S.
DAURISMO is the first and only Hedgehog pathway inhibitor approved for the treatment of AML In a randomized Phase 2 trial…
Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration (FDA) approved DAURISMO™ (glasdegib), a once-da…
Summary Agios and Celgene partnership's lead IDH2 inhibiting AML candidate enasidenib is under priority review for its NDA…